Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
95 Results for "
PLK3 PBD
" in MedChemExpress (MCE) Product Catalog:
Products (95)
95 Results for "PLK3 PBD" in MCE Product Catalog:
Cat. No.: HY-P706325
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PLK3; Proliferation-Related Kinase; Prev. CNK; Polo-Like Kinase 3; FNK; PLK-3; PRK; Polo-Like Kinase 3 (Drosophila); Cytokine-Inducible Serine/Threonine-Protein Kinase; Cytokine-Inducible Kinase; Serine/Threonine-Protein Kinase PLK3; Polo Like Kinase 3; FGF-Inducible Kinase
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P2289A
Synonyms: PBD-1 TFA
Cat. No.: HY-N15384
CAS No.: 148180-61-4
Category:
Flavonoids Wrightia arborea (Dennst.) Mabb. Plants Other Flavonoids Apocynaceae Extract Isoflavones
Target:
Target:
Cat. No.: HY-11003R
CAS No.: 660868-91-7
Synonyms: GW843682 (Standard)
Research Areas:
GW843682X (Standard) is the analytical standard of GW843682X (HY-11003). This product is intended for research and analytical applications. GW843682X is a selective, ATP-competitive inhibitor of PLK1 and PLK3, with IC50s of 2.2 nM and 9.1 nM, respectively, and is also >100-fold selective against ～30 other Kinases.
Cat. No.: HY-12135
CAS No.: 1239513-63-3
Target:
Research Areas:
Poloxipan is a pan-specific polo-like kinase (PLK) inhibitor that can inhibit a non-catalytic region at the C-terminus called the Polo-box domain (PBD) found in kinases. The IC50 values for Poloxipan against the PBDs of PLK-1/2/3 are 3.2 μM, 1.7 μM, and 3.0 μM, respectively. Poloxipan also inhibits other phospho-tyrosine binding domains, such as the forkhead-associated (FHA) domain of CHK-2, the WW domain of peptidyl-prolyl cis/trans isomerase (PIN1), and the phospho-tyrosine binding domains of STAT1/3/5 and lymphocyte-specific protein tyrosine kinase's SH2 domain. Poloxipan can be used in cancer research .
Cat. No.: HY-W076556
CAS No.: 330970-70-2
Synonyms: ((Allyloxy)carbonyl)-L-valyl-L-alanine
Target:
Research Areas:
Alloc-Val-Ala-OH (((Allyloxy)carbonyl)-L-valyl-L-alanine) is a building block in the synthesis of Tesirine, a clinical antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. The Val-Ala will specifically be cleaved by Cathepsin B. The Alloc group is stable to treatment with piperidine and TFA, but can be easily removed under mild conditions by palladium catalyzed allyl transfer.
Cat. No.: HY-P991236
Synonyms: DHES0815A antibody; RG-6148 antibody
Target:
Research Areas:
Cat. No.: HY-184863
CAS No.: 1034617-66-7
Target:
Research Areas:
PLK1-IN-17 is a potent PLK1 inhibitor with an IC50 of 2 nM. PLK1-IN-17 shows high selectivity for PLK2 and CDK2/A, moderate selectivity for PLK3, only weak activity against CK2, FLT3 and NEK6, and no activity against PDGFR, ALK and another 37 kinases. PLK1-IN-17 inhibits the proliferation of ovarian cancer cells and can be used in ovarian cancer-related research .
Cat. No.: HY-111090
CAS No.: 929095-23-8
Target:
Research Areas:
GSK461364 analogue 1 is a thiophene-based PLK1 inhibitor with a PLK1 IC50 of 2 nM and a PLK3 IC50 of 630 nM. GSK461364 analogue 1 also acts as an inhibitor of Nek2 kinase (IC50: 21 nM). GSK461364 analogue 1 has a solubility of ≥190 μM in pH 7.4 PBS and a human plasma protein binding rate of 91.5%. GSK461364 analogue 1 can be used in studies related to colon cancer, lung cancer, breast cancer and ovarian cancer .
Cat. No.: HY-171718
CAS No.: 550356-40-6
Research Areas:
seco-CBI-PBD dimer is a CBI-PBD heterodimer and a minor groove DNA crosslinker. seco-CBI-PBD dimer exhibits cytotoxicity against human tumor cells at sub-pM to low nM levels, shows low sensitivity to P-glycoprotein-mediated drug resistance, and can serve as an ADC payload. seco-CBI-PBD dimer can be used in studies of uterine cancer, breast cancer, non-small cell lung cancer, etc.
Cat. No.: HY-181051
CAS No.: 3068378-51-5
Target:
Research Areas:
PLK1-IN-16 is a selective polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.25 nM. PLK1-IN-16 exhibits lower inhibitory potency against PLK2 and PLK3, induces G2 phase cell cycle arrest, induces apoptosis, and exhibits antiproliferative activity against tumor cells. PLK1-IN-16 can be stable under simulated gastric acid environmental conditions, and acceptable CYP 450 inhibition. PLK1-IN-16 can be used for the study of triple-negative breast cancer (TNBC), breast cancer, leukemia .
Cat. No.: HY-185494
CAS No.: 1661824-39-0
Research Areas:
Mal-Val-Lys-PAB-CBI-PBD dimer is a Drug-Linker Conjugates for ADC. Mal-Val-Lys-PAB-CBI-PBD dimer consists of the ADC Cytotoxin CBI-PBD dimer and a linker Mal-Val-Lys-PAB. Mal-Val-Lys-PAB-CBI-PBD dimer exhibits alkylating activity at A-T-rich DNA minor groove adenine residues, disrupting DNA integrity. Mal-Val-Lys-PAB-CBI-PBD dimer induces cancer cell growth inhibition and cellular death. Mal-Val-Lys-PAB-CBI-PBD dimer can be used for the research of cancer .
Cat. No.: HY-185493
CAS No.: 1661823-95-5
Target:
Research Areas:
Mal-VC-PAB-seco-CBI-PBD dimer is a highly active drug-linker conjugate. Mal-VC-PAB-seco-CBI-PBD dimer integrates the DNA-damaging effects of two distinct types of compounds: seco-cyclopropabenzindoline (seco-CBI) and pyrrolobenzodiazepine (PBD). Mal-VC-PAB-seco-CBI-PBD dimer is linked via a valine-alanine (VC) linker cleavable by cathepsin B and achieves targeted delivery relying on monoclonal antibodies. Mal-VC-PAB-seco-CBI-PBD dimer is applicable for cancer research .
Cat. No.: HY-185495
CAS No.: 1884642-01-6
Target:
Research Areas:
seco-CBI-PBD-disulfide linker is a conjugate of an ADC drug toxin molecule and a linker, consisting of two potent DNA-damaging moieties seco-CBI, PBD (HY-101127), and a disulfide linker .
Cat. No.: HY-N7057A
CAS No.: 63718-65-0
Synonyms: Pelargonic acid ammonium
Nonanoic acid (Pelargonic acid) ammonium is a naturally-occurring saturated fatty acid with nine carbon atoms. Nonanoic acid significantly reduces bacterial translocation, enhances antibacterial activity, and remarkably increases the secretion of porcine β-defensins 1 (pBD-1) and pBD-2 .
Cat. No.: HY-P991970
Cat. No.: HY-188141
CAS No.: 3057557-03-3
Target:
Research Areas:
Allopole-A is a Plk1 inhibitor with an IC50 of 1.4-2.5 μM against human Plk1 PBD1. Allopole-A binds to the allosteric W-F pocket in Plk1 PBD1, displacing the L2 loop, thereby disrupting water-mediated phospho-ligand binding interactions and promoting inhibitory interactions between the kinase domain and PBD to suppress Plk1 kinase activity. Allopole-A can be used in studies of human cancers with plk1 overexpression .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
